Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 872 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage II Prostate Carcinoma Clear all
Active, not recruiting Phase 2 Interventional

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT03682289
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Ceralasertib, Olaparib, Durvalumab
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery

NCT00685516
View directory record Official record
Conditions
Prostate Cancer
Interventions
green tea, placebo, decaffeinated black tea
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

NCT00349557
View directory record Official record
Conditions
Prostate Cancer
Interventions
bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT)
Drug · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

NCT00861107
View directory record Official record
Conditions
Metastatic Cancer
Interventions
AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

NCT00946881
View directory record Official record
Conditions
Prostate Cancer
Interventions
WST 11 -mediated -VTP
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

NCT03103321
View directory record Official record
Conditions
Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer, PSA Level Five to Ten, PSA Level Less Than Five, PSA Level Ten to Fifty
Interventions
Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
28
States / cities
Bellflower, California • Los Angeles, California • Oakland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 15, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MVA 5T4, Docetaxel
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

NCT00305747
View directory record Official record
Conditions
Prostate Cancer
Interventions
BR-DIM
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 15, 2026, 2:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

NCT04969315
View directory record Official record
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer (CRC), Endometrial Cancer, Ovarian Cancer
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 15, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

NCT00479635
View directory record Official record
Conditions
Prostate Cancer
Interventions
TPI 287
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palm Springs, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 15, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

NCT04060394
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)

NCT00678054
View directory record Official record
Conditions
Prostate Cancer
Interventions
GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of HE3235 in Patients With Prostate Cancer

NCT00716794
View directory record Official record
Conditions
Prostate Cancer
Interventions
HE3235
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • Roseville, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00528866
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, flutamide, LHRH agonist, 3-dimensional conformal radiation therapy, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
69
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Acupuncture Treatment for Hot Flashes Study

NCT00421902
View directory record Official record
Conditions
Prostate Cancer
Interventions
Acupuncture
Procedure
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00015977
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, recombinant interleukin-12
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 15, 2026, 2:31 AM EDT
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer

NCT00037024
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue, Malnutrition, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
fatigue assessment and management, nutritional support, physical therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Duke University
Other
Eligibility
65 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Hypofractionated Radiotherapy for Prostate Cancer

NCT00214097
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 15, 2026, 2:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

NCT06574880
View directory record Official record
Conditions
Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions
Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Angela Y. Jia, MD PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 15, 2026, 2:31 AM EDT
Withdrawn Phase 2 Interventional

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

NCT05445882
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
Bintrafusp alfa, N-803, BN-Brachyury
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

NCT01799278
View directory record Official record
Conditions
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Interventions
MLN8237
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Detroit, Michigan • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 15, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

NCT00919035
View directory record Official record
Conditions
Prostate Cancer
Interventions
torisel
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 15, 2026, 2:31 AM EDT